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Immunoglobulin (CD79a) binding protein 1 (IGBP1) is universally overexpressed
in lung adenocarcinoma and exerts an anti-apoptotic effect by binding to PP2Ac.
However, the molecular mechanism of IGBP1 overexpression is still unclear. In
the present study, we used a microRNA (miRNA) array and TargetScan Human
software to detect IGBP1-related miRNAs that regulate IGBP1 expression. The
miRNA array analysis revealed more than 100 miRNAs that are dysregulated in
early invasive adenocarcinoma. On the other hand, in silico analysis using Tar-
getScan Human revealed 79 miRNAs that are associated with IGBP1 protein
expression. Among the miRNAs selected by miRNA array analysis, six (miR-34b,
miR-138, miR-374a, miR-374b, miR-1909, miR-3941) were also included among
those selected by TargetScan analysis. Real-time reverse transcription PCR (real-
time RT-PCR) showed that the six microRNAs were downregulated in invasive
adenocarcinoma (IGBP1+) relative to adjacent normal lung tissue (IGBP1).
Among these microRNAs, only miR-34b and miR-3941 depressed luciferase activity
by targeting 30UTR-IGBP1 in the luciferase vector. We transfected miR-34b and
miR-3941 into lung adenocarcinoma cell lines (A549, PC-9), and both of them sup-
pressed IGBP1 expression and cell proliferation. Moreover, the transfected miR-
34b and miR-3941 induced apoptosis of a lung adenocarcinoma cell line, similarly
to the effect of siIGBP1 RNA. As well as miR-34b, we found that miR-3941 tar-
geted IGBP1 specifically and was able to exclusively downregulate IGBP1 expres-
sion. These findings indicate that suppression of miR-3941 has an important role
in the progression of lung adenocarcinoma at an early stage.
L ung adenocarcinoma is a leading cause of death in Japan,the USA and Europe.(1,2) Even for patients with pathologi-
cal stage I lung cancer, the 5-year survival rate is 66–83%,
which is far from satisfactory. However, Noguchi et al.(3,4)
have indicated that very early-stage adenocarcinomas classified
into Noguchi types A and B, and type C’, show a very favor-
able prognosis. Recently, Travis et al.(5,6) defined these two
distinct groups of early-stage lung adenocarcinomas as adeno-
carcinoma in situ (AIS) and minimally invasive adenocarci-
noma (MIA), respectively, and this concept was accepted in
the latest (4th) edition of the WHO classification of lung
tumors. Although the biology of AIS and MIA is still unclear,
with the exception of EGFR mutation, early-stage adenocarci-
nomas are known to have a very low frequency of gene abnor-
malities such as mutations of k-ras and p53, amplifications of
PIK3CA, BRAF and HER2, and translocations of ALK, ROS
and RET that have been reported in advanced lung adenocarci-
nomas.(7–10) Therefore, it would be very informative and perti-
nent to clarify the specific genetic, epigenetic and phenotypic
abnormalities that occur during the progression of very early-
stage adenocarcinoma to early but invasive adenocarcinoma.
We have been focusing on such abnormalities at the early
stage of lung adenocarcinogenesis and reported several, such
as amplification of ECT2, demethylation of SFN, and overex-
pression of OCIAD2 and immunoglobulin (CD79a) binding
protein 1 (IGBP1).(11–14)
Among them, IGBP1 was initially identified as a signal
transduction molecule coprecipitating with MB1 (Iga) of the
B-cell antigen receptor (BCR) complex, and was later found to
be broadly expressed in various organs. IGBP1 has been char-
acterized as an associated and regulatory component of the cat-
alytic subunits of protein phosphatase (PP) 2, PP4, and PP6.
Protein phosphatase 2A (PP2A) is the most abundant phos-
phatase in mammalian cells, playing important roles in cell
growth and cell cycle control.(15–25) PP2Ac is one of the cat-
alytic subunits of PP2A, and interaction between IGBP1 and
PP2Ac enhances the catalytic activity of the latter and alters
its substrate specificity. Binding of PP2Ac to IGBP1 also leads
to acquisition of anti-apoptosis function.(26) Li et al.(27) have
found that lactoferrin binds specifically to IGBP1 in a lung
adenocarcinoma cell line, thus triggering apoptosis. Subse-
quently, Sakashita et al.(14) reported that the level of IGBP1
protein expression increases along with lung adenocarcinoma
progression, being significantly associated with patient
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outcome. Therefore, clarification of the molecular mechanism
of IGBP1 overexpression would shed important light on the
early progression of lung adenocarcinoma and might indicate
suitable candidate molecules for targeted therapy.
Generally, gene amplification, point mutation, and methyla-
tion of the promoter region have been reported as causes of
dysregulated gene expression. However, few reports have
focused on such alterations in IGBP1. In addition to these
genetic and epigenetic alterations, microRNAs (miRNAs) are
reported to be involved in the abnormal expression of oncoge-
nes or anti-oncogenes. miRNAs are endogenous non-coding
small RNAs (20–22 nucleotides) that can also regulate gene
expression by binding to target messenger RNAs (mRNAs).
miRNAs are associated with various cell processes such as cell
development, differentiation, proliferation, carcinogenesis and
apoptosis. Dysregulation of miRNAs has been especially asso-
ciated with various human cancers, such as lymphoma, colon
carcinoma, gastric carcinoma, lung carcinoma, breast carci-
noma, and brain tumors.(28–33) Thus, many miRNAs appear to
play oncogenic or anti-oncogenic roles in the development and
progression of cancers. Chen et al.(34) have reported that
down-regulation of miR-34b leads to high expression of
IGBP1, suggesting that miRNA is an essential regulator of
IGBP1 expression.
In the present study using microRNA array analysis and in
silico analysis with TargetScan Human, we focused on several
candidate miRNAs that influence the expression of IGBP1.
Materials and Methods
Tissue samples and cell lines. Three fresh specimens of
human early lung adenocarcinoma, seven frozen specimens
of human lung adenocarcinoma in situ, and six frozen speci-
mens of human invasive lung adenocarcinoma, together with
paired samples of adjacent normal lung tissue, were obtained
from patients who had undergone surgical resection at Tsu-
kuba University Hospital (Ibaraki, Japan). Informed consent
for study of their materials had been obtained from all of
the patients. The A549 and PC-9 human lung adenocarci-
noma cell lines were purchased from RIKEN Cell Bank
(Ibaraki, Japan). A549 was maintained in Dulbecco’s modi-
fied Eagle medium/F12 (DMEM/F12) (Thermo Fisher Scien-
tific, Waltham, MA, USA) supplemented with 10% fetal
bovine serum (FBS) (Corning, NY, USA). PC-9 was main-
tained in RPMI 1640 (Thermo Fisher Scientific) supple-
mented with 10% FBS. All cells were cultured in a 5% CO2
incubator at 37°C.
microRNA array. Total RNA was extracted from three fresh
tumor cells of early lung adenocarcinoma (two cases of small
invasive adenocarcinoma and one case of minimally invasive
adenocarcinoma), which were collected by scratching directly
from the cut surface of freshly resected material, as the tumor
employed was very small (<2.0 cm in diameter). The samples
were then subjected to microRNA array analysis using miR-
CURY LNA (Exiqon, Vedbaek, Denmark). The threshold for
identifying the dysregulated miRNAs was a twofold change
(either down or up).
Immunohistochemistry. The 4-lm-thick sections were
deparaffinized and rehydrated, then pretreated by autoclaving
at 120°C for 5 min in 10 mM citrate buffer (pH 6.0). The
slides were treated with chemMate POD Blocking Solution
(Dako, Copenhagen, Denmark) at room temperature for 5 min
to block any endogenous peroxidase activity before incubation
with the anti-IGBP1 antibody (1:250; Sigma-Aldrich Co., St.
Louis, MO, USA). The antibody was applied for 30 min, fol-
lowed by incubation with the secondary antibody (EnVision+-
DualLink; Dako) for 30 min. The slides were then incubated
in DAB/Tris solution and finally counterstained with hema-
toxylin.
Total RNA isolation and real-time reverse transcription PCR.
Total RNA was extracted using a mirVana miRNA isolation
kit (Thermo Fisher Scientific) in accordance with the manufac-
turer’s instructions. For analysis of each mature miRNA, total
RNA was reverse-transcribed using a TaqMan MicroRNA
Reverse Transcription Kit (Thermo Fisher Scientific) along
with each miRNA-specific primer (Thermo Fisher Scientific).
U6 snRNA was used as an endogenous control. Real-time
reverse transcription PCR (real-time RT-PCR) for miRNA was
performed with TaqMan Universal PCR Master Mix II
(Thermo Fisher Scientific) on a GeneAmpVR 7300 Sequence
Detection System (Thermo Fisher Scientific) in accordance
with the manufacturer’s protocol.
For detection of IGBP1 mRNA, reverse transcription and
qRT-PCR were performed using a Highcapacity cDNA Rev-
erse Transcription Kit (Thermo Fisher Scientific) and Power
SYBR Green PCR Master mix (Thermo Fisher Scientific) on a
GeneAmp 7300 Sequence Detection System (Thermo Fisher
Scientific) in accordance with the manufacturer’s protocol. The
primers used for real-time RT-PCR of IGBP1 were:
forward; 50-GGCATCAACTTCTAACTCATCTCG-30,
reverse; 50-CTCATACCAGTCACTCACCGTCAT-30.
The primers used for real-time RT-PCR of 18S were:
forward; 50-ACTCAACACGGGAAACCTCA-30,
reverse; 50-AACCAGACAAATCGCTCCAC-30.
Transfection using miRNA mimic and IGBP1-specific siRNA.
miRNA mimic (Thermo Fisher Scientific), IGBP1-specific
siRNA (siIGBP1), or scrambled RNA (Stealth RNAi Negative
Control Medium GC Duplex; Thermo Fisher Scientific), and a
nucleic acid transferring agent (lipofectamine RNAiMAX;
Thermo Fisher Scientific), were incubated together in Opti-
MEM/ reduced serum medium (Thermo Fisher Scientific) in
six-well plates for 20 min at room temperature. Antibiotic-free
medium containing PC-9 or A549 cells at a density of
6.0 9 104/mL was added to each well to give a final miRNA
concentration of 30 nM. The cells were then incubated at
37°C in a CO2 incubator for 24–72 h. The sequence of
siIGBP1 was: 50-GAUCCUGAGAGAAAGAGACUCUUCA-30.
Luciferase reporter assay. A firefly luciferase reporter plasmid
containing the IGBP1 30 untranslated region (UTR) (pMirTar-
get-IGBP1-30UTR, cat no #SC204862) was purchased from
Origene Technologies (Rockville, MD, USA). To generate
pMirTarget-IGBP1-30UTR-Mut, which carried the mutation in
the target region of miR-3941, the WT clone served as tem-
plate for amplifying the IGBP1 30UTR mutant using primers
harboring the mutation, and was cloned into the SgfI and MluI
sites in the pMirTarget plasmid.
A549 cells seeded in 96-well plates were co-transfected with
pMirTaget-IGBP1-30UTR or pMirTaget-IGBP1-30UTR-Mut
and the miRNA mimic or negative control RNA duplex (NC
duplex; Thermo Fisher Scientific) using FuGene HD transfec-
tion reagent (Promega, Madison, WI, USA) and lipofectamine
RNAiMAX (Thermo Fisher Scientific), respectively. The pRL-
TK (Promega) was transfected simultaneously as a normaliza-
tion control. Cells were collected 48 h after transfection, and
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luciferase activity was measured using a dual-luciferase repor-
ter assay kit (Promega) and microplate reader (Varioskan
LUX; Thermo Fisher Scientific).
Western blotting. Total cell lysates were prepared on ice
with M-PER Mammalian Protein Extraction Reagent (Thermo
Fisher Scientific) containing protease and phosphatase inhibi-
tor cocktail (Thermo Fisher Scientific). The lysates were cen-
trifuged for 10 min at 4°C, and the insoluble fraction was
discarded. The total protein in the soluble lysates was mea-
sured using a BCA protein assay kit (Thermo Fisher Scien-
tific). Total protein aliquots (20 lg) were mixed with loading
buffer supplemented with DTT, denatured at 95°C for 5 min,
and electrophoresed on 10% or 12% Mini-PROTEAN TGX
Precast Gels (Bio-Rad Laboratories, Hercules, CA, USA).
The proteins were then transferred to polyvinylidene difluo-
ride membranes using an iBlot gel transfer system (Thermo
Fisher Scientific). The blots were blocked and then probed
with antibodies against the following proteins: IGBP1 (1:200;
Sigma-Aldrich Co), beta-actin (ACTB) (1:5000; Thermo
Fisher Scientific), caspase 3 (1:500; Cell Signaling Technol-
ogy, Denvers, MA, USA), cleaved caspase 3 (1:500; Cell
Signaling Technology), and poly ADP ribose polymerase
(PARP) (1:1000; Cell Signaling Technology). After extensive
washing, immunoreactivity was detected with specific sec-
ondary antibodies conjugated to horseradish peroxidase. Pro-
tein bands were visualized using SuperSignal West Femto
Maximum Sensitivity substrate (Thermo Fisher Scientific)
and the ChemiDoc Touch Imaging System (Bio-Rad Labora-
tories).
The positive control for apoptosis detection was a lysate of
PC-9 cells treated with camptothecin (Sigma-Aldrich Co, final
concentration 10 lM). The negative control was a lysate of
non-treated PC-9 cells.
Cell proliferation assay. Cells were seeded in six-well plates,
cultured for the indicated time periods, and counted with a
hematocytometer. Three replicates were prepared for each
group. WST-8 assay was carried out using a cell counting kit-
8 (DOJINDO, Kumamoto, Japan) in accordance with the man-
ufacturer’s protocol. The IGBP1 ORF sequence was cloned
into the pF4A_CMV Flexi vector (Promega) using a Flexi
Vector system (Promega). pF4A_CMV_IGBP1 (pIGBP1) was
simultaneously transfected with miR-3941 into cells as a
rescue experiment. pGFP was used as a negative control for
the plasmid.
Results
Six candidate miRNAs targeting IGBP1. To search for dysregu-
lated miRNAs associated with IGBP1 expression, we per-
formed a microRNA array assay using fresh materials
collected from surgically resected lung adenocarcinoma. First,
the expression profiles of 1223 miRNAs in two small invasive
lung adenocarcinomas and one MIA were compared using
miRCURY LNA (Exiqon). The two small invasive adenocarci-
nomas were positive for IGBP1 expression whereas MIA was
IGBP1-negative (Fig. 1a,b). The results indicated that more
than 100 miRNAs showed a difference in expression between
the small invasive adenocarcinomas and MIA. The results of
the microRNA array are available in Gene Expression Omni-
bus (GEO accession number: GSE89750). On the other hand,
TargetScan Human (ver.6.2) analysis of a miRNA database
predicted that 79 human miRNAs might target IGBP1. Among
the miRNAs highlighted by the microRNA array, six (miR-
34b, miR-138, miR-374a, miR-374b, miR-1909, miR-3941)
were also included among those highlighted in TargetScan
analysis (Fig. 1c). Therefore we considered these six miRNAs
to be candidates for association with IGBP1 regulation during
progression of adenocarcinoma (Table 1).
Expression of the six candidate miRNAs was then examined
by real-time RT-PCR using samples from seven cases of human
6 candidate microRNAs
miR-34b, miR-138
miR-374a, miR-374b
miR-1909, miR-3941
microRNA array showed
More than 100 
microRNAs
TargetScan Human
showed
79 microRNAs
(a)
(c)
(b)
Fig. 1. IGBP1 immunohistochemistry of the tissues
used for microRNA array and the number of
miRNAs selected by microRNA array analysis and
TargetScan Human analysis. (a) Invasive adeno-
carcinoma, (b) minimally invasive adenocarcinoma.
(c) Among the miRNAs highlighted by the
microRNA array, six were also included among
those highlighted by TargetScan Human analysis.
Table 1. The summary of six candidate microRNAs
miRNA
Fold change
(microRNA array)
P-value
(real-time RT-PCR)
miR-34b 2.021424 0.012457753
miR-138 0.40756 0.000816333
miR-374a 2.193465 0.010328695
miR-374b 0.343731 0.233730387
miR-1909 2.435487 0.032925251
miR-3941 0.465127 0.03385292
Fold change representing the abundance of microRNA in type C rela-
tive to MIA. The P value was calculated for the difference between
normal lung tissue and invasive adenocarcinoma.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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lung adenocarcinoma in situ and six cases of human invasive
lung adenocarcinoma in comparison with the corresponding
adjacent normal lung tissues. All of the adenocarcinomas in situ
were immunohistochemically negative for IGBP1, and the inva-
sive lung adenocarcinomas were immunohistochemically posi-
tive for IGBP1 (Fig. 2a). Among the six miRNAs, expression of
miR-34b, miR-138, miR-374a, miR-1909, and miR-3941 was
significantly lower in invasive adenocarcinoma than in adjacent
normal lung tissue (Fig. 2b, Table 1). miR-374b also tended to
be downregulated in tumor tissue, but not to a significant degree.
Expression of miR-34b, miR-138, miR-374a, and miR-3941
tended to become lower during progression of adenocarcinoma
(normal > AIS > invasive adenocarcinoma).
Direct targeting of IGBP1 by miR-34b and miR-3941. Next, we
carried out dual-luciferase reporter assay analysis to identify
miRNAs that directly targeted IGBP1. A firefly luciferase repor-
ter plasmid containing the IGBP1 30UTR was co-transfected into
A549 cells along with the candidate miRNAs. The IGBP1
30UTR sequence contained all of the binding sites of the six can-
didate miRNAs. As shown in Figure 3(a), only miR-34b and
miR-3941 inhibited luciferase activity (by 20% and 40%, respec-
tively). However, none of the other candidates (miR-138, miR-
374a, miR-374b, and miR-1909) inhibited the luciferase activity.
In contrast, miR-3941 failed to bind to the mutated 30UTR and
showed no inhibitory effect on luciferase activity (Fig. 3b,c).
Interestingly, transfected miR-3941 suppressed IGBP1
expression by <50% relative to the control, whereas miR-34b
had no suppressive effect (Fig. 3d). On the other hand, both
miRNAs suppressed IGBP1 protein expression in comparison
to the negative control (Fig. 3e,f).
Inhibition of cell proliferation and induction of apoptosis by
miR-3941 in lung adenocarcinoma cell lines. Based on the results
shown in Figure 3, we focused on miR-34b and miR-3941 and
evaluated their effects on cell proliferation and apoptosis in
lung adenocarcinoma cell lines.
Cell proliferation was evaluated by cell counting after trans-
fection with miR-34b, miR-3941, or siIGBP1 RNA. Scrambled
RNA was used as a negative control. miR-34b and miR-3941
significantly suppressed the proliferation of both PC-9 and A549
cells (Fig. 4a,b), the effects being more marked in the former
than in the latter. Moreover, we carried out WST-8 assay after
transfection with miR-3941 and the IGBP1 ORF clone (pIGBP1)
to validate whether IGBP1 overexpression abrogated the growth
suppression induced by miR-3941. As expected, although miR-
3941 reduced cell proliferation similarly to Figure 4(a,b), IGBP1
overexpression significantly recovered the cell growth (Fig. 4c).
Although single transfection with pIGBP1 did not lead to an
increase of cell proliferation, this might have been because the
cell line we used for this experiment, PC-9, originally had a high
level of endogenous IGBP1 and proliferative capacity.
Because IGBP1 has an anti-apoptotic action, we examined the
apoptotic effect of miR-34b and miR-3941 in PC-9 cells. After
transfection with miR-3941 or siIGBP1, the level of IGBP1
expression was significantly suppressed, and both cleaved cas-
pase-3 and cleaved PARP were significantly induced (Fig. 4d).
However, the effect of miR-34b was less than that of miR-3941.
Discussion
In this study, we examined miRNAs that might regulate
IGBP1 expression in lung adenocarcinoma at an early stage.
microRNA array analysis and in silico screening revealed that
six miRNAs (miR-34b, miR-138, miR-374a, miR-374b, miR-
1909, miR-3941) might be associated with the regulation of
IGBP1 expression (Fig. 1), and that the expression levels of
the five miRNAs (miR-34b, miR-138, miR-374a, miR-1909,
miR-3941) were significantly suppressed in the invasive adeno-
carcinomas examined (Fig. 2). Moreover, the expression levels
of miR-34b, miR-138, miR-374a, and miR-3941 tended to
become lower during progression of adenocarcinoma (nor-
mal > AIS > invasive adenocarcinoma). Many previous
reports have described the association of the miR-34 family
(miR-34a, mir-34b, miR-34c) with malignant tumors, and they
appear to act as key regulators of downstream p53 expression.
Many of their targets are involved in the cell cycle, prolifera-
tion, and apoptosis, and include c-MYC, CDK6, c-MET, and
bcl-2.(35) miR-138 is associated with several types of malig-
nancy. In non-small lung carcinoma, miR-138 is known to be
a tumor suppressor targeting several genes, such as enhancer
of zeste homolog 2 (EHZ2) and cyclin D3.(36,37) Some reports
have described the association of miR-1909 and miR-374 with
malignant tumors. For example, it has been shown that miR-
1909 is included in the specific miRNA signature associated
with complete pathological response to neoadjuvant chemora-
diotherapy in locally advanced rectal cancer,(38) and another
report has suggested that several miRNAs including miR-374
are deregulated in small cell lung carcinoma.(39) There are also
a limited number of reports indicating that miR-3941 is associ-
ated with malignant tumors. In acute lymphoblastic leukemia
(ALL), Lu et al.(40) have reported that 30 UTR polymorphism
of the insulin-like growth factor (IGF) gene influences anneal-
ing activity with several miRNAs including miR-3941, and is
associated with patient outcome. The present report is a first to
have indicated a biological effect of miR-3941 in solid tumors.
Among the six miRNAs we investigated, miR-34b and miR-
3941 directly annealed with the IGBP1 30UTR and the expres-
sion of IGBP1 was suppressed by the transfection with both
miRNAs. These results indicate that the expression of IGBP1
is directly regulated by these two miRNAs (Figs. 3,4). Until
now, miR-34b has been the only miRNA reported to regulate
IGBP1 expression.(34) As reported previously, miR-34b sup-
pressed the proliferation of a lung adenocarcinoma cell line to
a degree equivalent to the effect of miR-3941 (Fig. 4a). How-
ever, it did not suppress IGBP1 expression significantly. On
the other hand, miR-3941 not only suppressed IGBP1 expres-
sion significantly, but also induced apoptosis more effectively
than miR-34b (Figs. 3,4). Moreover, IGBP1 overexpression
abrogated the cell growth suppression induced by miR-3941
(Fig. 4c). Therefore, although miR-34b might be a strong
tumor suppressor, IGBP1 is only one of its many target genes,
and its tumor-suppressive role via IGBP1 may only be a sec-
ondary, rather than a main effect. On the other hand, miR-
3941 is thought to interact with IGBP1 more strongly and
more specifically than miR-34b. Hence, miR-3941 is thought
to be a specific miRNA that regulates IGBP1 expression.
Real-time RT-PCR was performed to investigate endogenous
expression of miR-3941 in PC-9, A549, PL16T (a cell line of
atypical adenomatous hyperplasia, a precancerous lesion of
lung adenocarcinoma), and PL16B (a normal bronchial epithe-
lium cell line), but expression of miR-3941 in each of these
cell lines was below the detection sensitivity (data not shown).
IGBP1 is thought not to regulate miR-3941 because siIGBP1
did not increase the expression of miR-3941 (lower than the
detection sensitivity). The suppression of miR-3941 in not only
PC-9 and A549 but also in PL16T and PL16B may be due to
a change in the phenotype of PL16T and PL16B, established
in our laboratory, because SV40 large T antigen was induced
to immortalize.(41)
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Fig. 2. (a) Representative examples of IGBP1 immunohistochemistry in adjacent normal lung (left side), adenocarcinoma in situ (middle), and
invasive adenocarcinoma (right side). Normal lung tissue and all of the adenocarcinomas in situ showed no reactivity with the anti-IGBP1 anti-
body, whereas all of the invasive adenocarcinomas showed positive reactivity. (b) Real-time RT-PCR analysis of the expression of the six selected
miRNAs. All of the miRNAs except miR-374b were significantly suppressed in invasive adenocarcinoma, compared with the normal counterpart
tissues. Expression of miR-34b, miR-138, miR-374a, and miR-3941 tended to become lower during progression of adenocarcinoma (nor-
mal > AIS > invasive adenocarcinoma).
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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The growth-inhibitory effects of miR-3941 and miR-34b
were greater in PC-9 than in A549 (Fig. 4a,b). Binding of
PP2Ac to IGBP1 leads to suppression of PP2A phosphatase
activity, resulting in acquisition of anti-apoptosis function
through bcl-2 activation. Furthermore, PP2A inhibits Akt
downstream of EGFR.(42) PC-9 has EGFR mutation and A549
has KRAS mutation. Thus, the effects of IGBP1 inhibition
might have been more pronounced in PC-9 than in A549
because of collateral inhibition of the EGFR cascade.
Recently, miRNA mimics have emerged as excellent
therapeutic agents, and many studies of the therapeutic
effects of miRNAs have been reported, not only alone but
also in combination with conventional chemotherapeutic
agents or other miRNAs.(43,44) In this study, we demon-
strated that miR-3941 is a specific miRNA that targets and
regulates IGBP1 expression. As indicated before, IGBP1 is
widely expressed in lung adenocarcinoma and its expression
is significantly associated with prognosis. Therefore,
Fig. 3. (a) Luciferase reporter assay. Among the six miRNAs, miR-34b and miR-3941 showed significant inhibition of luciferase activity. (b) The puta-
tive target region of miRNA-3941 on the 30UTR of IGBP1. The mutant generated at the miR-3941 target region in IGBP1 30UTR is underlined and serves
as a control. (c) Luciferase reporter assay using either the wild-type (WT) or mutant (Mut) IGBP1 30-UTR plasmid. (d) Real-time RT-PCR for IGBP1 using
the cells transfected with miRNAs. After transfection of the six miRNAs into A549 cells, miR-3941 suppressed IGBP1 expression to <50% relative to the
control, but miR-34b had no suppressive effect. (e) Western blotting using the cells transfected with miRNAs. (f) The density of bands in western blot-
ting (e) were digitalized by Image J software (U.S. National Institutes of Health, Bethesda, Maryland, USA). Each density was normalized by those of
ACTB. At the protein level, both miRNAs suppressed IGBP1 protein expression relative to the negative control. NC: negative control RNA duplex.
Fig. 4. (a, b) Cell counts were performed after
transfection of PC-9 or A549 cells with miR-34b,
miR-3941, or siIGBP1 RNA. Both miR-34b and miR-
3941 significantly suppressed the proliferation of
both cell lines. (c) WST-8 assay after transfection of
PC-9 cells with miR-3941 and pIGBP1. IGBP1
overexpression abrogated the cell growth
suppression induced by miR-3941. pGFP was used as
a negative control for the plasmid. (d) After
transfection of miR-34b, miR-3941, or siIGBP1 RNA,
miR-3941 significantly suppressed the expression of
IGBP1, and induced both cleaved caspase-3 and
cleaved PARP. Negative control: PC-9 lysate, Positive
control: PC-9 lysate treated with camptothecin
(10 lM).
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miR-3941 could be a promising therapeutic agent for lung
adenocarcinoma.
In summary, we have found that miR-3941 targets and down-
regulates IGBP1 most specifically in lung adenocarcinoma cell
line, and induces apoptosis. Reduced expression of miR-3941
and overexpression of IGBP1 are thought to be associated with
anti-apoptotic events during the course of lung adenocarcinoma
progression. Therefore, suppression of IGBP1 using a miR-3941
mimic might be very specific and effective therapeutic strategy.
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